Viral vector manufacturingThe SIDUS® platform combines our biological materials (cell lines and vector systems) with our in-depth experience and complete protocol systems for manufacturing viral vector-based vaccine, oncolytic and gene therapy products.
Cell lines for viral vector manufacturing
The mammalian cells commonly used for viral vector manufacturing are Vero cells (for measles and VSV vectors) and HEK293 cells (for AAV, adeno and lentiviral vectors) as well as derivatives thereof. For both cell types, we have generated research-grade cell banks (R&D) and fully tested and released master cell banks (GMP). Next to these parental cell lines, we have subcloned versions of Vero cells. These cells allow the production of substantially higher amounts of virus particles per cell for certain viruses.
Stable, high yield manufacturing
In addition, we have also developed engineered versions of HEK293 cells. These cells allow stable, high yield manufacturing of infectious virus particles. For instance, stable expression of certain adenoviral vector-derived proteins in HEK293 has been able to provide a cell platform capable of supporting the robust growth of diverse human and non-human adenoviral serotypes. Further addition of regulatory elements that control transgene expression ensure production of adenoviral vectors carrying transgenes whose protein products may otherwise interfere with cell growth or vector assembly. This results in high yields in engineered HEK293 cells.